newswire, breaking biotechnology and pharma news

Thursday, April 19, 2012

Medical Technology Stock Alert; PositiveID Corporation's (OTCBB:PSID) iglucose Mobile Health Solution for Diabetes Management to be Featured at CTIA Wireless Emerging Technology Awards Showcase

DELRAY BEACH, Fla. - April 19, 2012 ( newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced its FDA-cleared iglucose(R) mobile health system for diabetes management will be featured at the CTIA Emerging Technology (E-Tech) Awards Showcase at the International CTIA Wireless 2012 show from May 8-10, 2012 at the Ernest N. Morial Convention Center in New Orleans, LA. iglucose will be showcased within the category entitled Enterprise & Vertical Market Solution: Healthcare & Wellness.
PositiveID's FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating data from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals. This makes it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. Family members have greater peace of mind; now parents of children with diabetes can receive text messages to let them know their children are testing while at school. iglucose does not require the use of a cell phone or a wireless plan.
iglucose was designed with the needs of healthcare professionals and people with diabetes in mind. It is simple to use and conveniently fits within a pocket or purse. Usability tests conducted as part of the iglucose FDA review process demonstrated 100 percent of consumers were able to use the device regardless of their age. After initial enrollment there are no technology requirements for the end user. Users simply connect their glucometer to iglucose and push a button. The iglucose system creates a variety of reports and communicates according to the user's preferences via online access, email, fax or SMS text.
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. The Company is continually adding to this list of supported glucose meters. For more information on iglucose, visit
The International CTIA Wireless show draws more than 40,000 qualified attendees every year, occupies more than 300,000 sq. ft. of exhibit space, hosts over 1,000 exhibitors, attracts more than 1,100 press and analysts worldwide, and offers top-level speakers and the most comprehensive educational programming in the industry. CTIA--The Wireless Association(R) ( is an international organization representing the wireless communications industry.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Allison Tomek
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on
Visit the company profile:
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and  company profile . More info: and disclosures:
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:

No comments:

Post a Comment